Zeria Pharmaceutical Co., Ltd.
Stock Price Chart
2026/01/16 UpdatedPrice Trend
2026/01/16 UpdatedPrice & Trading Details
2026/01/16 UpdatedPRICE
TRADING
Analyst Recommendations 1 analysts
Updated 2026/01/11Shareholder Composition
Updated 2026/01/11Dividend History 4Years Growth
Updated 2026/01/11| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥48 | +6.7% |
| 2024 | ¥45 | +2.3% |
| 2023 | ¥44 | +22.2% |
| 2022 | ¥36 | +5.9% |
| 2021 | ¥34 | - |
Financial Performance
2026/01/11 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥59,533M | ¥68,383M | ¥75,725M | ¥87,311M |
| Gross Profit | ¥42,148M | ¥49,489M | ¥55,501M | ¥63,960M |
| Operating Income | ¥6,366M | ¥9,015M | ¥9,622M | ¥12,198M |
| Pretax Income | ¥6,037M | ¥7,610M | ¥9,966M | ¥13,071M |
| Net Income | ¥3,961M | ¥6,196M | ¥7,731M | ¥9,936M |
| EPS | ¥87.76 | ¥140.26 | ¥175.39 | ¥225.42 |
| Operating Margin | 10.69% | 13.18% | 12.71% | 13.97% |
| Balance Sheet | ||||
| Total Assets | ¥124,282M | ¥135,035M | ¥150,534M | ¥159,172M |
| Total Equity | ¥54,895M | ¥65,450M | ¥79,623M | ¥89,540M |
| Total Liabilities | ¥69,388M | ¥69,585M | ¥70,911M | ¥69,632M |
| Cash | ¥11,704M | ¥16,219M | ¥20,324M | ¥23,593M |
| Interest-bearing Debt | ¥52,229M | ¥49,432M | ¥46,228M | ¥41,164M |
| Equity Ratio | 44.17% | 48.47% | 52.89% | 56.25% |
| D/E Ratio | 0.95 | 0.76 | 0.58 | 0.46 |
| Cash Flow | ||||
| Operating CF | ¥8,951M | ¥13,157M | ¥12,184M | ¥12,922M |
| Investing CF | -¥2,893M | -¥2,575M | -¥3,952M | -¥1,051M |
| Financing CF | -¥4,841M | -¥7,415M | -¥8,124M | -¥7,757M |
| Free CF | ¥7,530M | ¥10,500M | ¥8,285M | ¥10,188M |
| Efficiency | ||||
| ROE | 7.22% | 9.47% | 9.71% | 11.10% |
| ROA | 3.19% | 4.59% | 5.14% | 6.24% |
Latest IR Information
-
No IR information found for this company.
Searched stock code: 4559
Latest News (5 items)
-
Average Analyst Rating: none
Average Target Price: ¥2,400
Rating Score: - (Based on 1 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Zeria Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures, sells, imports, and exports pharmaceuticals, non-pharmaceutical products, veterinary pharmaceuticals, agricultural and industrial chemicals, and reagents in Japan and internationally. The company operates through Ethical Pharmaceuticals Business and Consumer Healthcare Business segments. It also provides cosmetics, health foods, alcoholic beverages, soft drinks, food additives, livestock feed, hygienic goods, medical devices, health equipment, hygiene facilities and equipment, beauty appliances, and measuring and analytical equipment. The company also offers products in the gastrointestinal field, including therapeutic agents for functional dyspepsia, ulcerative colitis, Crohn's disease, and gastritis and ulcers; zinc containing anti-ulcerants; oral bowel cleansing agents; laxatives; therapeutic agents for hypophosphatemia, and iron deficiency anemia; long-acting calcium channel blockers; oral NSAID; anti-leukopenia after radiotherapy products; and non-steroidal anti-inflammatory ophthalmic solutions. In addition, it provides consumer healthcare products, such as nutritional health drugs, remedies for gastrointestinal diseases, western herbal medicines, cold remedies, ophthalmic solutions, anti-inflammatory/analgesics, hemorroidal remedies, dermal remedies, quasi-drugs/cosmetics, nutrient tonics, soft drinks/health foods, and food for specified health uses. Further, the company engages in insurance agency and real estate business. The company was formerly known as Zeria Yakusho Kenkyusho Co., Ltd. and changed its name to Zeria Pharmaceutical Co., Ltd. in May 1970. Zeria Pharmaceutical Co., Ltd. was incorporated in 1955 and is headquartered in Tokyo, Japan.